// App-Quantinova.ai

e16503 : Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.

Researchers

Presenter

  • Carlo Buonerba

Principal Investigators

  • Guru Sonpavde

  • Gregory Russell Pond

  • Martina Pagliuca

  • Sabrina Rossetti

  • Gaetano Facchini

  • Sarah Scagliarini

  • Bruno Daniele

  • Piera Federico

  • Franco Morelli

  • Giacomo Carteni

  • Matteo Ferro

  • Giuseppe Lucarelli

  • Teresa Bellelli

  • Sabino De Placido

  • Giuseppe di Lorenzo

Medical Centers

  • Medical Oncology Unit, Department of Clinical Medicine, Federico II University, Naples, Italy

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Ontario Clinical Oncology Group, Hamilton, ON, Canada

  • Universita Federico II di Napoli, Napoli, Italy

  • Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy, Naples, Italy

  • Cardarelli Hospital, Naples, Italy

  • G.Rummo Hospital, Benevento, Italy

  • University Federico II, Napoli, Italy

  • Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, San Giovanni Rotondo, Italy

  • Medical Oncology, Cardarelli Hospital, Napoli, Italy

  • IEO, Milan, Italy

  • University of Bari, Bari, Italy

  • ASL Salerno, Vallo Della Lucania, Italy

  • Department of Clinical Oncology and Endocrinology and Rare Tumors Reference Center, Federico II University, Naples, Italy

Locations

  • United States

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved